Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

NCT00257491 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Telmisartan
DRUG: Telmisartan/HCTZ

Sponsor

Boehringer Ingelheim